PT-141 did not start as anything to do with sexual function. It started as a suntan. In the early 1980s, a laboratory in Arizona was trying to make a peptide that could darken skin without sunlight, and the compound that grew out of that work took an unexpected turn that reshaped a whole line of melanocortin research. The story of bremelanotide is really the story of a research accident, and of the decades of chemistry that came before and after it.
The melanocortin lineage: α-MSH and its analogs
To understand where PT-141 came from, you have to start with a natural signalling molecule called α-melanocyte-stimulating hormone, or α-MSH. It is a short peptide, thirteen amino acids long, cleaved from a larger precursor protein called proopiomelanocortin (POMC). α-MSH is one of several “melanocortin” peptides, and they act on a family of five receptors labelled MC1R through MC5R. Those receptors do very different jobs depending on where they sit in the body: MC1R is tied to skin and hair pigmentation, while MC3R and MC4R, concentrated in the central nervous system, are linked to energy balance and, as later work suggested, aspects of sexual signalling.
Natural α-MSH breaks down quickly, which makes it awkward to study. So in the 1980s, researchers Mac E. Hadley and Victor J. Hruby at the University of Arizona set out to build sturdier synthetic versions. Their goal was pigmentation: a peptide that could trigger melanin production, in theory offering a protective tan without ultraviolet exposure. They produced Melanotan I (later developed as afamelanotide, a linear analog) and then Melanotan II (MT-II), a cyclic structure designed for greater stability and potency.
The discovery: an unexpected result with MT-II
Melanotan II is where the plan diverged from the outcome. During early testing of the compound, researchers observed effects that had nothing to do with tanning, including reports of arousal and spontaneous erections in male subjects. This was not the hypothesis anyone had written down. But it pointed to something real: because MT-II was a broad melanocortin agonist, it was also activating the central MC3R and MC4R pathways, not only the MC1R pigmentation pathway the team had been chasing.
That observation split the research into two directions. The pigmentation side of MT-II drifted into an unregulated grey market. The central-nervous-system side became a genuine pharmaceutical question, and it was picked up by Palatin Technologies, a New Jersey biotech, around the turn of the millennium.
From MT-II to PT-141: refining the molecule
Palatin’s approach was to stop working with Melanotan II directly and instead focus on one of its breakdown products. PT-141, given the name bremelanotide, is closely related to MT-II but structurally distinct: where MT-II carries a C-terminal amide, bremelanotide is the deamidated form, ending in a hydroxyl group. It is often described as an active metabolite of Melanotan II. That single change matters, because it shifts the compound’s character away from the MC1R pigmentation effect and toward the central MC3R and MC4R receptors that had produced the surprising early observations.
Through the early 2000s, Palatin studied bremelanotide as a nasal spray. A double-blind, placebo-controlled evaluation of intranasal PT-141 in healthy males and men with mild-to-moderate erectile dysfunction was published in 2004 (Rosen and colleagues, International Journal of Impotence Research), and the intranasal route was investigated for both male and female indications. That formulation ran into a wall. Around 2007–2008, regulators raised concerns about transient increases in blood pressure seen with the nasal delivery, which produced higher and less predictable plasma levels, and the intranasal program was halted.
The pivot to injection and FDA review
Rather than abandon the compound, Palatin changed how it was delivered, moving to subcutaneous administration, which appeared to give a more controlled profile. The company redirected the program toward hypoactive sexual desire disorder (HSDD) in premenopausal women and ran a pair of Phase III trials under the name RECONNECT.
That work led to the milestone that most people associate with the molecule today. On June 21, 2019, the U.S. Food and Drug Administration approved bremelanotide, marketed as Vyleesi, for acquired, generalized HSDD in premenopausal women. It was developed by Palatin and, at approval, licensed to AMAG Pharmaceuticals for the North American market. Notably, the FDA labelling states that the precise mechanism is not fully established; the effect is believed to involve activation of central melanocortin receptors, the same MC3R and MC4R pathways that trace back to that first accidental observation with MT-II. Outside this specific approved indication, much of what is discussed about PT-141 remains at the level of laboratory and preclinical research rather than settled clinical fact.
What makes the history worth telling is how little of it was planned. A peptide built to imitate a tanning hormone became a tool for probing the melanocortin system, and a byproduct of that peptide became one of the few melanocortin agonists ever to clear a regulatory review. The chemistry that started with Hadley and Hruby’s α-MSH analogs is still the backbone of how researchers think about these receptors.
→ PT-141 Research Guide · COA available PT-141 range
Research use only. PT-141 (bremelanotide) is supplied by Vero Labs strictly as a research compound for laboratory investigation. It is not offered for human or animal use, self-administration, or any therapeutic or diagnostic purpose. Every batch is independently third-party lab-tested for identity and purity, with a published Certificate of Analysis (COA) available for each product.